The information contained within this announcement is deemed
by the Company to constitute inside information as stipulated under
the UK version of the EU Market Abuse Regulation 596/2014 which is
part of UK law by virtue of the European Union (Withdrawal) Act
2018, as amended and supplemented from time to time. Upon the
publication of this announcement, this inside information is now
considered to be in the public domain.
23 May 2024
IXICO plc
("IXICO" or the
"Company")
Alzheimer's Disease (AD) trial
contract win.
IXICO plc (AIM: IXI), the medical
imaging advanced analytics company delivering insights in
neuroscience announces that it has signed a contract with the
Global Alzheimer's Platform Foundation® ("GAP") to support GAP's
planned Bio-Hermes 2 trial. The contract value is worth over £1
million over a 48-month term. The Company does not expect to adjust
its expectations of performance for the financial year ending 30
September 2024 ("FY24") following the receipt of this
contract.
In the Bio-Hermes 2 trial, IXICO
will apply its expertise to qualify approximately 30 participating
imaging centres for the collection of amyloid PET and tau PET
molecular imaging and MR Imaging scans from approximately 1,200
volunteers over the age of 60. The volunteers will be screened for
Preclinical Alzheimer's Disease, Prodromal AD, or Mild Dementia AD,
with IXICO providing both visual read and AI driven quantitative
analysis across all three imaging modalities used in the Bio-Hermes
2 trial.
Giulio Cerroni, Chief Executive
Officer of IXICO, commented:
"We are delighted to deepen our
long-term strategic partnership with GAP by building on the success
of the initial Bio-Hermes trial to now also be selected to deliver
all of the imaging analysis requirements of the Bio-Hermes 2 trial
across both MRI and PET. With the significant unmet medical need
for new therapies in Alzheimer's Disease, we are excited about the
prospects of deepening our collaboration with GAP in support of the
success of the Bio-Hermes 2 trial."
John Dwyer, President of Global
Alzheimer's Platform Foundation (GAP), commented:
"Our collaboration with IXICO for
neuroimaging and AI driven
quantitative analysis is a fundamental element of GAP's
innovative Bio-Hermes 2 trial, which is taking a novel approach to
incorporate a broad set of digital and blood biomarker results for
comparison across cognitively normal and impaired individuals.
We've also committed to an unprecedented level of participation by
traditionally underrepresented populations in AD studies so that
the insights generated by BH2 will benefit everyone impacted by
Alzheimer's and related dementias."
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets
Limited (Nominated Adviser
and
Sole Broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
| |
About
IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More
information is available on www.IXICO.com and
follow us on Twitter @IXICOnews